Virtual Library

Start Your Search

Zoltán Szász



Author of

  • +

    P2.01 - Advanced NSCLC (Not CME Accredited Session) (ID 950)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P2.01-95 - Assesment the Fitness for Chemotherapy of NSCLC Patients using 6MWT (ID 13745)

      16:45 - 18:00  |  Author(s): Zoltán Szász

      • Abstract
      • Slides

      Background

      Decision making in chemotherapy in multimorbid advanced NSCLC patients is a complex and challenging task. Physcian reported ECOG performance status (PS), being reproducible, is the gold standard of functional status quantification, when planning an oncology treatment. Inaccurate assesment of PS score is associated with an increased risk of treatment complications and therapy related deaths.

      The aim of study was to measure the correlation between 6-minute walking test (6MWT), PS and chemotherapy endurance and to study the role of 6MWT in predicting treatment complications and deaths.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      138 advanced stage (IIIA, IIIB, IV) NSCLC consented patients were enrolled in a prospective study. They were grouped according to their 6MWT results, and correlation with PS, BMI, FEV1, laboratory values, chemotherapy regimes and cycles were analyzed, with respect to the treatment complications and deaths as endpoints. Statistical analysis was performed with SPSS, Inc., Chicago, IL (level of significance < 0,05).

      4c3880bb027f159e801041b1021e88e8 Result

      Statistical correlation was found between the 6MWT and chemotherapy endurance. Low 6MWT results (with a cut-off of 360 and 300 m respectively) were significantly associated with a very high risk of hematologic complications (36% and 42%), hospitalization (42% and 56%) and 3-month mortality (45% and 69%). No statistical correlation was found between 6MWT to PS, age, FEV1, BMI and initial lab values.

      8eea62084ca7e541d918e823422bd82e Conclusion

      6MWT seems to be a simple, reliable and objective tool in assessing a patient’s fitness to palliative chemotherapy for advanced NSCLC. Optimisation of treatment protocols, using 6MWT as a supportive tool to facilitate PS assesment, might prevent overtreatment of the patient and abuse of health service/insurance budgets.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.